



CIN No. L24232PB1983PLC005426
D.L. No. 1800-OSP, 1804-B

GST No. 03AAACK6458M1ZB
I.E. Code No. 1293001210

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com

KWALITY PHARMACEUTICALS LTD.

Regd. Office: 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Date: June 03, 2022

To,
The Department of Corporate Services,
BSE Limited
Phioze Jeejeebhoy Towers
Dalal Street,
Mumbai -400001

Scrip Code: 533397

Subject: Intimation of In-Principle Approval for Migration from BSE SME Platform to BSE Main Board.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has received the In-Principle Approval from BSE Limited bearing Ref. No. LO/Migration/MJ/IP/77/2022-23, dated June 02, 2022 for migration of equity shares of the Company from BSE-SME platform to Main Board of BSE Limited.

Please find the enclosed herewith the copy of the In- Principle Approval of the BSE Limited.

Kindly acknowledge and take on your record.

For **Kwality Pharmaceuticals Limited**


Ramesh Arora
Managing Director
DIN: 00462656



LO/Migration/MJ/IP/77/2022-23

June 02, 2022

The Company Secretary
Kwality Pharmaceuticals Limited
Majitha Road, Village Nagkalan,
Amritsar , Punjab, 143601

Dear Sir/ Madam,

Re: In-principle Approval for Migration of Kwality Pharmaceuticals Limited from BSE SME Platform to BSE Mainboard

We refer to your Company's application dated April 09, 2022, for listing the equity shares on the BSE's Mainboard Trading Platform.

We are pleased to inform you that the same was considered by the Internal Listing Committee of the Exchange.

Accordingly, the Exchange is pleased to grant its in-principle approval to the Company's application for listing & trading its equity shares on the BSE Mainboard Platform. You are advised to complete the following formalities for listing of securities of the Company:

1. Letter of application for listing of shares on Main Board.
2. Information Memorandum of the Company in the format prescribed in Section 26 of the Companies Act 2013 read along with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and duly certified by the Managing Director/ Company Secretary (Hard/ Soft copy in email). The Information Memorandum must be as on date of filing the listing application consequent to In-principle Approval.
3. Listing Agreement as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. Latest Share holding pattern as per format provided by SEBI vide its circular no. CIR/CFD/CMD/13/2015 dated November 30, 2015 and financials as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
5. You are requested to pay Initial Listing Fees of Rs. 20,000/- and Annual Listing Fee of Rs. 3,00,000/- for the Financial Year 2022-23 along with applicable Taxes (Please refer the Schedule of Listing Fees available on BSE website).
<https://www.bseindia.com/markets/MarketInfo/DispNewNoticesCirculars.aspx?page=20220326-1>

Kindly forward us the above-mentioned documents / information at the earliest to enable us to process the matter. You are requested to note that this approval is valid for a period of **45 days** from the date of this letter.
Yours faithfully,

For BSE Limited

Sd/-
Rupal Khandelwal
Assistant General Manager

Sd/-
Raghavendra Bhat
Deputy Manager